Revive Therapeutics

Can a State Fast-Track a Psychedelic Breakthrough? Inside Texas’ Plan to Fund Ibogaine TrialsMay 28, 2025
Texas is on the verge of launching the largest publicly funded psychedelic research initiative in U.S. history: a $50 million public-private partnership to support FDA-approvable ibogaine trials. The initiative has drawn support from high-profile figures like Rick Perry, but also concerns over safety, cost, access, and the lack of recognition for Indigenous knowledge. We take a look at the bold plan, the political manoeuvring that made it possible, and the questions that still remain.
Gilgamesh’s Next-Gen Psychedelic GM-2505 Prints Impressive Results in Phase 2a Major Depressive Disorder StudyMay 27, 2025
As Gilgamesh Pharmaceuticals is set to share positive results from its Phase 2a study of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder later today at ASCP, we speak with the company’s Chief Strategy and Development Officer Jorge Quiroz and Chief Operating Officer Yoni Falkson to dig a little deeper into the study, its results, and the company’s plans for the candidate.
Matt Zorn, the Government’s Former Adversary, Is Now Its Psychedelics CzarMay 24, 2025
Matt Zorn made his name suing federal agencies over cannabis and psychedelics policy. Now, he’s inside the system as Deputy General Counsel at HHS, with what appears to be a mandate over psychedelics reform. Here, we recount Zorn's path from 'thorn in the side' of the federal government to insider, what we might expect from him in his new role, and how insiders are reacting to the news.
Pα+ Psychedelic Bulletin #198: New Data Offers Look at Spravato’s Long-Term Use, Highlights Psychedelic Opportunity; MAHA Report Slams Psychiatric Meds; Momentum Builds for BeckleyMay 23, 2025
New Data Offers Look at Spravato’s Long-Term Use, Highlights Opportunity for Psychedelics • MAHA Report Slams Psychiatric Drug Use Among America’s Youth, Trump Era Drug Policy Priorities Raise Questions for Psychedelics • Beckley Psytech’s Small Study Supports Adjunctive Use of 5-MeO-DMT with SSRIs in TRD • and more...
Psychedelics in Japan: Dr. Hiroyuki Uchida on Studies, Stigma, and the Road AheadMay 21, 2025
As global interest in psychedelic therapies grows, Japan is beginning to chart its own path, grounded in cultural nuance, regulatory caution, and scientific rigour. In this interview, Dr. Hiroyuki Uchida of Keio University discusses his journey into psychedelic research, the challenges of launching Japan’s first psilocybin trials, and the steps being taken to ensure a safe, culturally appropriate psychedelic future.

Revive Therapeutics

Latest News

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents

Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

Join our Newsletter

Psychedelic Alpha

Quick Links

Newsletter

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights